前沿生物(688221.SH)：FB7013境内生产药品注册临床试验申请获得受理通知书

Core Viewpoint - Frontier Biotech (688221.SH) has submitted a clinical trial application for its self-developed siRNA drug targeting the MASP-2 protein, aimed at treating primary immunoglobulin A nephropathy (IgA nephropathy) [1] Group 1 - The clinical trial application for the drug, named FB7013 injection, was submitted to the National Medical Products Administration on December 22, 2025 [1] - On December 31, 2025, the company received a notice of acceptance from the National Medical Products Administration for the clinical trial application of FB7013 [1] - The drug is specifically intended for the treatment of primary immunoglobulin A nephropathy (IgA nephropathy) [1]